Company Profile – Abbott Laboratories

June 2017
Table of Contents
• Company Insight Slide 3
‒ Company Overview

• Strategy & Strategic Plan Targets Slide 7

‒ Business Strategy

‒ Business Challenges

• Acquisitions & Divestitures Slide 20

‒ Acquisitions

‒ Divestitures

• Technology Landscape Slide 26

‒ IT Strategy

‒ Technology Landscape

|2
COMPANY INSIGHT
Abbott Laboratories
Company Overview (1/3)

Headquarters Employees Sales and Operation

Illinois, US • 75,000 (December 2016) N/A
• 94,000 (Following the acquisition of
St. Jude Medical (2016)

Revenue Net income Major competitors

$20.9 billion (FY2016) N/A • Johnson & Johnson
• Pfizer
• Novartis

|4
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Company Overview (2/3)
• Overview:
‒ Abbott Laboratories is a healthcare company which is engaged in the discovery, development, manufacture and sale of a range of healthcare
products

‒ The Company operates through four segments:

o Established Pharmaceutical Products: It includes line of branded generic pharmaceutical products related to Cardiology and metabolic,
Primary care, Women’s health and Gastroenterology

o Diagnostic Products: It includes sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-
care testing sites. This segment takes account of the Core Laboratories Diagnostics, Molecular Diagnostics, Point of Care and Ibis
diagnostic divisions

o Nutritional Products: It includes sales of a broad line of adult and pediatric nutritional products

o Vascular Products: It includes sales of coronary, endovascular, structural heart, vessel closure and other medical device products. This
segment consists of the Vascular and Electrophysiology Products

‒ Non-reportable segments include the Diabetes Care and Medical Optics segments

|5
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Company Overview (3/3)
‒ Fiscal Year for Abbott ends on December 31

• History:
‒ In 1888, Dr. Wallace C. Abbott began production of “alkaloidal” medicine granules in the rear of his People’s Drug Store in Chicago. Remedies
contained the active ingredients of plants and herbs

‒ In 1894, Abbott Alkaloidal Company was incorporated

‒ In 1959, Abbott adopted the “A” logo, a classic of industrial design that remains the cornerstone of their visual identity till date

‒ In 2013, a new era began for Abbott, as a more consumer-focused company, they created a new, Fortune 200 corporation, AbbVie, from
their former proprietary pharmaceutical business

|6
Source: Industry Reporting; Group Website and Report
STRATEGY & STRATEGIC PLAN
TARGETS
Abbott Laboratories
Business Strategy (1/12)

Mission Statement: “Live not just longer, but better”

• Vision Statement: “To make Abbott the world’s leading healthcare company in the markets in which we compete — the company that
sets the standard in innovation, impact, and performance. To this end, we shape the company to achieve maximum competitiveness. To
us, that means building significant and leading positions in large and growing markets.”

• Strategy: Abbott seeks to continually shape their business for sustained growth and maintain a well-balanced, diversified approach. For
this Abbott has generated strategies based on their individual segments: Nutrition, Branded Generic Pharmaceuticals, Diagnostics and
Medical Devices

‒ As a whole, the company appears to be moving in the following direction in creating long term shareholder value:

o Shaping the Company

o Capture Share with Innovation

o Innovative Solutions to Improve Care

|8
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (2/12)
Nutrition
• Build strong globally
recognized brands
• Capture share with
innovation
• Grow and shape
markets
Branded Generic
Pharmaceuticals
• Strengthening local
presence and
capabilities
• Market-specific
innovation
• Building locally-relevant
portfolios in key
therapeutic areas
Diagnostics Medical Devices
• Launch next-generation • Effectively integrate
Alinity systems Abbott and St. Jude
• Continue to expand in Medical businesses
priority emerging • Capture share in large
markets established segments
• Continue to drive • Shape and grow
above-market growth in emerging categories
developed markets

Strategy

Innovative
Shaping Capture
Solutions
the Share with
to Improve
Company Innovation
Care

|9
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (3/12)
Shaping the Company
• Abbott has been engaged in shaping the company to achieve it’s long term strategy for which it has acquired companies with opportunities for
further growth and divested some of its existing businesses

“When I say shaping the company, it's shaping the company for the long-term, for the long-term success of our Company and for the value
that we bring to our customers, to our patients and to our shareholders as well.”

- Brian Yoor, Chief Financial Officer and SVP, Abbott Laboratories, 2016
• In January 2017, Abbott announced the completion of the acquisition of St. Jude Medical, a medical device company. The transaction provides
Abbott with expanded opportunities for future growth and is an important part of the company's ongoing effort to develop a strong, diverse
portfolio of devices, diagnostics, nutritionals and branded generic pharmaceuticals. The

agreement had been announced in April, 2016

‒ In October 2016, Abbott and St. Jude Medical announced an agreement in principle to sell certain products to Terumo Corporation. The
transaction reflects a purchase price of approximately $1.12 billion and is subject to the successful completion of Abbott's acquisition of St.
Jude Medical and antitrust regulatory approvals

| 10
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (4/12)
Shaping the Company (Cont.)
‒ In April 2016, Abbott and St. Jude Medical announced a definitive agreement for Abbott to acquire St. Jude Medical, creating a premier
medical device leader with top positions in high-growth cardiovascular markets, including atrial fibrillation, structural heart and heart failure
as well as a leading position in the high-growth neuromodulation market. Under the agreement, St. Jude Medical shareholders
received $46.75 in cash and 0.8708 shares of Abbott common stock, representing total consideration of approximately $85 per share

• In February 2016, Abbott and Alere announced a definitive agreement for Abbott to acquire Alere, manufacturer of rapid point-of-care
diagnostic tests, which expand edAbbott's global diagnostics presence and leadership

‒ On December 2016, Abbott filed a complaint to terminate its proposed acquisition of Alere based on the substantial loss in Alere's value
following the merger agreement. Under terms of the merger agreement, Abbott may terminate the transaction if adverse events materially
change Alere's long-term prospects

‒ In April 2017, Abbott and Alere announced that the companies have agreed to amend the existing terms of their agreement for Abbott's
acquisition of Alere

| 11
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (5/12)
Shaping the Company (Cont.)
• In September 2016, Abbott announced that it would sell Abbott Medical Optics, its vision care business, to Johnson & Johnson for $4.325
billion in cash

"We've been actively and strategically shaping our portfolio, which has recently focused on developing leadership positions in cardiovascular
devices and expanding diagnostics.“

-Miles D. White, Chairman and Chief executive officer of Abbott, 2016

| 12
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (6/12)
Capture Share with Innovation
• Abbott has a wide range of products for healthcare professionals. With a slogan “Partner for a healthier tomorrow”, Abbott commits on
achieving better health, together. Following are the initiatives taken to capture share among healthcare professionals:

‒ Cardiac:

o Insertable Cardiac Monitor (ICM): In May 2017, Abbott announced first use of the new Confirm Rx Insertable Cardiac Monitor (ICM), the
world's first smartphone compatible ICM that will help physicians identify difficult to detect cardiac arrhythmias, to help guide therapy.
The Confirm Rx ICM is designed to continuously monitor a patient's heart rhythm and proactively transmit information via the myMerlin
mobile app, allowing physicians to follow their patients remotely and accurately diagnose arrhythmias

o TactiCath Contact Force Ablation Catheter: In May 2017, Abbott announced European conformity of the TactiCath Contact Force Ablation
Catheter, Sensor Enabled, developed to make it easier for physicians to more effectively treat atrial fibrillation (AF), a condition in which
the upper chambers of the heart beat too fast. When integrated with Abbott's EnSite Precision cardiac mapping system, physicians are
able to utilize dual impedance and magnetic technologies to help more precisely model the heart

| 13
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (7/12)
Capture Share with Innovation (Cont.)
o FlexAbility Ablation Catheter: In March 2017, Abbott announced US Food and Drug Administration (FDA) approval of the FlexAbility
Ablation Catheter, Sensor Enabled designed to improve the versatility and precision during cardiac ablation procedures to treat atrial
flutter, a type of irregular heartbeat. The FlexAbility Ablation Catheter, Sensor Enabled is the first ablation catheter from Abbott that
helps collect both electrical current resistance (impedance) and magnetic data to facilitate detailed, accurate mapping as well as assist in
the treatment of sites that trigger or sustain abnormal heart rhythms

o CardioMEMS HF System: In March 2017, a clinical research presented Abbott's CardioMEMS HF System as an effective real-world
approach to reduce heart failure hospitalizations and combat the rising cost of heart failure. The CardioMEMS HF System is the first and
only US Food and Drug Administration-approved monitor that, when used by physicians to manage heart failure, has been shown to
significantly reduce heart failure hospital admissions and improve the quality of life in patients with heart failure

o EnSite Precision cardiac and Advisor Fl Circular Mapping Catheter: In January 2017, Abbott announced the US launch and the first
commercial uses of the new EnSite Precision cardiac mapping system and Advisor FL Circular Mapping Catheter, Sensor Enabled to map
cardiac arrhythmias during ablation treatments

| 14
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (8/12)
Capture Share with Innovation (Cont.)
‒ Blood:
o In February 2017, Abbott announced that the US Food and Drug Administration (FDA) has authorized its molecular test, the Abbott RealTime
ZIKA test, to detect Zika virus in whole blood for emergency use. This is the first molecular test made by a commercial manufacturer
authorized to detect Zika in whole blood samples. The Abbott RealTime ZIKA test is designed for use on the m2000 RealTime System – the
company's molecular
o Alinity: In January 2017, Abbott announced its Alinity, a system for blood and plasma screening received CE Mark and is now available
in Europe and other countries that recognize CE Mark. The new testing solution is designed to screen blood and plasma faster and more
efficiently within a smaller footprint than Abbott's current systems
§ In August 2016, Abbott announced the introduction of Alinity, its harmonized family of next-generation systems across immunoassay,
clinical chemistry, point of care, hematology, blood and plasma screening and molecular diagnostics. Each Alinity platform includes a
number of features to help institutions, clinicians and laboratorians better navigate through a pressure-packed health care environment
§ In January 2017, Abbott announced its Alinity ci-series instruments for clinical chemistry and immunoassay diagnostics also obtained CE
Mark and are now available in Europe and other countries that recognize CE Mark. These innovative testing solutions help labs run more
tests in less time, reduce human error and increase testing productivity

| 15
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (9/12)
Capture Share with Innovation (Cont.)
‒ Vision:
o Tecnis Symfony Intraocular Lenses: In July 2016, Abbott announced that the US Food and Drug Administration (FDA) approved the Tecnis
Symfony Intraocular Lenses for the treatment of cataracts. The first in a new category of intraocular lenses (IOLs), the Tecnis Symfony lenses
are the only lenses in the US that provide a full range of continuous high-quality vision following cataract surgery, while also mitigating the
effects of presbyopia by helping people focus on near objects. The FDA approval includes a version of the lens for people with astigmatism, the
Tecnis Symfony Toric IOL
‒ Others:
o In February 2017, Abbott announced US Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for
both the Assurity MRI pacemaker and the Tendril MRI pacing lead. Patients implanted with these low-voltage devices have the ability to
undergo full body magnetic resonance imaging (MRI) scans, if required. With the approval, the Assurity MRI pacemaker was the world's
smallest, longest-lasting wireless MRI-compatible pacemaker
o In September 2016, Abbott announced that the US Food and Drug Administration (FDA) approved the company's FreeStyle Libre Pro system, a
revolutionary continuous glucose monitoring (CGM) system for healthcare professionals to use with their patients with diabetes. FreeStyle
Libre Pro system is designed to empower healthcare professionals to provide better diabetes management for diabetes patients

| 16
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (10/12)
Innovative Solutions to Improve Care
• The company has been providing improved solutions for consumer with a motive “ To help you live your best life at all stages”. Following mentioned
are the product available for consumers as per their business area:
• Nutritional Product:
‒ In April 2017, Abbott, the maker of Ensure, has developed two new science-based nutrition drinks for patients undergoing surgery:
Ensure Surgery Immunonutrition Shake and Ensure Pre-Surgery Clear Nutrition Drink, helping to reduce insulin resistance and improve patient
outcomes
‒ In September 2016, EAS Sports Nutrition introduced a Myoplex Ketogenic shake to help athletes shift the body from relying on glucose for energy
to instead tapping into stored fat. EAS Sports Nutrition is a product of Abbott
• Patient Monitoring System:
‒ In Jan 2017, Abbott announced the European launch of the Proclaim DRG Neurostimulation System, designed to deliver dorsal root ganglion
(DRG) stimulation to patients suffering from chronic neuropathic pain. Through the Proclaim platform's Bluetooth wireless technology and iOS
software, the Proclaim DRG Neurostimulation System offers patients improved experience of how they interact with their device, which may lead
more patients to consider DRG stimulation for the treatment of chronic neuropathic pain, compared to current systems with traditional
controllers that can be difficult to operate

| 17
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (11/12)
Innovative Solutions to Improve Care (Cont.)
o Abbott was the first company to offer a neurostimulation device designed for DRG therapy and targeted relief of certain types of chronic
pain. The approval of the Proclaim DRG Neurostimulation System provides patients with chronic neuropathic pain access to the company's
Proclaim platform, a magnetic resonance (MR)-conditional recharge-free system offering best-in-class programming, upgradeability and
increased battery capacity
‒ In May 2017, Abbott announced that the French Health Ministry had granted national reimbursement across France for FreeStyle Libre—Abbott's
glucose monitoring technology that removes the need for routine finger sticks for people with both Type 1 and Type 2 diabetes
• Government Regulations
‒ Abbott is subject to numerous governmental regulations and it can be costly to comply with these regulations and to develop compliant products
and processes
‒ Abbott Laboratories has appeared to be using genetically modified (GMO) ingredients (from modified corn and soy) in some products in its
nutritional lines, including its Similac Soy Isomil infant formula products
o In April 2015, For the third year in a row, shareholders at Abbott Laboratories' annual meeting voted on a proposal to disclose which
nutritional products contain genetically modified organisms (GMOs), and what actions the company is taking to reduce or eliminate those
ingredients. The shareholder resolution was filed by environmental health advocacy organization As You Sow

| 18
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Business Strategy (12/12)
Innovative Solutions to Improve Care (Cont.)

"Abbott has serious transparency issues around the ingredients it sources. The vast majority of GMOs are engineered to sell more pesticides, and
pesticide overuse is causing major environmental problems. Consumers associate Abbott brands with environmental problems, and this is a
material risk to investors.”

- Andrew Behar, CEO of As You Sow, 2016

• Point-of-care-diagnostics Business
‒ On January 2016, Abbott entered into a merger agreement to acquire Alere
o After the merger agreement, several key developments occurred with respect to Alere, including three new, separate investigations by the US
Department of Justice, delays in the filing of Alere's required annual (Form 10-K) and quarterly (Form 10-Q) SEC reports, management's disclosure
of unremediated material weaknesses over financial reporting, the issuance of an opinion by Alere's auditors that Alere could not maintain effective
internal control because of material weaknesses over financial reporting related to revenue recognition, a product recall following notice from the
US Food and Drug Administration, and the revocation of the Medicare billing privileges of an Alere business unit by the Centers for Medicare &
Medicaid Services
‒ In August 2016, Alere filed a lawsuit in accusing Abbott of acting and proceeding slowly on closing the deal
‒ In a court filing in November 2016, Abbott charged Alere with breaching a contractual obligation to provide information about its business

| 19
Source: Industry Reporting; Group Website and Report
ACQUISITIONS & DIVESTITURES
Abbott Laboratories
Acquisitions (1/3)
Acquisitions
Acquirer Target Deal Period Deal Value Region Deal Description
• Glomed was a leading Vietnamese drug manufacturer
Abbott Glomed
September 2016 US • The deal ensured long-term growth of Abbott in Vietnam and
Pharmaceutical NA
(acquired) helped further strengthen Abbott’s ability to serve patients in the
Company
country with innovative, high-quality healthcare solutions
• St. Jude Medical was an American global medical device company
• Abbott Laboratories agreed to buy heart-device maker St. Jude Medical
to gain bargaining power with hospitals
Abbott St. Jude Medical April 2016 $25 billion US • Abbott acquired products like pacemakers, heart valves and devices to
treat atrial fibrillation from St. Jude Medical which will enabled the
company to expand its medical devise products along with its existing
generic-drugs business in emerging markets and nutrition products
• Kalila Medical was a private medical device company developing next-
generation access technologies used in cardiac electrophysiology
procedures for the treatment of heart rhythm disorders, including atrial
Abbott Kalila Medical April 2016 NA US
fibrillation
• Abbott gained Kalila’s technology to expand their portfolio of tools for
the treatment of atrial fibrillation and other heart rhythm disorders

| 21
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Acquisitions (2/3)
Acquisitions
Acquirer Target Deal Period Deal Value Region Deal Description
• Alere was the leader in point of care diagnostics
Abbott Alere February 2016 NA US • Abbott and Alere announced a definitive agreement for Abbott to
acquire Alere, which expands Abbott's global diagnostics presence and
leadership
• Tendyne Holdings was a US-based medical device company that
develops minimally invasive transcatheter mitral valves
• This acquisition allowed Abbott Laboratories to expand its portfolio of
Abbott Tendyne Holdings July 2015 NA US transcatheter mitral valves

• Veropharm was a leading Russian pharmaceutical company

• Abbott established a manufacturing footprint in Russia and obtained a
Abbott Veropharm June 2014 $495 million Russia portfolio of medicines that is well aligned with Abbott's pharmaceutical
therapeutic areas of focus

• Topera was a private, venture-backed medical device company focused

in developing electrophysiology technologies to improve the diagnosis
and treatment of atrial fibrillation, a common heart rhythm disorder
Abbott Topera October 2014 $250 million US
• Abbott enters large and growing Catheter-Based Electrophysiology
market with next-generation technologies to improve treatment of
people with Atrial Fibrillation
| 22
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Acquisitions (3/3)
Acquisitions
Acquirer Target Deal Period Deal Value Region Deal Description
• CFR Pharmaceuticals was a Chilean pharmaceutical company engaged
in the development, production, and sale of pharmaceutical drugs in 15
CFR Latin American countries and in Asia
Abbott May 2014 $2.9 billion US
Pharmaceuticals • Through purchase of the controlling interest and tender offers, Abbott
indirectly acquired more than 99 percent of CFR's ordinary shares for
approximately $2.9 billion
• OptiMedica Corporation was a privately-held, Silicon Valley-based
ophthalmic device company
Abbott OptiMedica July 2013 $400 million US • The acquisition expanded Abbott's vision care business into the
femtosecond laser-assisted cataract surgery market

• IDEV Technologies was a privately held company focused on developing

next-generation medical devices for use by interventional radiologists,
vascular surgeons and cardiologists
Abbott IDEV Technologies July 2013 $310 million US
• IDEV technologies' SUPERA Veritas Medical Device provides an
innovative treatment for patients with Peripheral Artery Disease (PAD)
around the world

| 23
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Divestitures (1/2)
Divestitures

Acquirer Target Deal Period Deal Value Region Deal Description

• Terumo reached an agreement with Abbott and St. Jude Medical to

St. Jude acquire certain products owned by both for a total of $1.12 billion
Terumo Medical and October 2016 $1.12 billion US
• Terumo acquired St Jude Medical’s Angio-Seal and FemoSeal vascular
Abbott
closure product lines and Abbott’s Vado Steerable Sheath

• Abbott sold its eye care business to Johnson & Johnson for about $4.33
billion in cash to focus on cardiovascular devices and diagnostics
business
• Abbott divested the business as a part of shaping its portfolio for long
Abbott US term growth
Johnson &
Medical September 2016 $4.33 billion
Johnson
Optics ‘We've been actively and strategically shaping our portfolio, which has
recently focused on developing leadership positions in cardiovascular
devices and expanding diagnostics.’
-Miles White, CEO, 2016

| 24
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Divestitures (2/2)
Divestitures

Acquirer Target Deal Period Deal Value Region Deal Description

• Generic drug maker Mylan bought Abbott Laboratories' branded

specialty and generics business in developed markets outside the US in
a $5.3 billion deal
Mylan Abbott July 2014 $5.3 billion US
• Abbott planed relatively quickly to sell its stake in the new company
and use the proceeds to boost it's earnings, such as by acquiring more
medical devices or buying back its shares

| 25
Source: Industry Reporting; Group Website and Report
TECHNOLOGY LANDSCAPE
Abbott Laboratories
IT Strategy
IT Outsourcing to Wipro
• In February 2016, Abbott Labs informed 180 of its information-technology workers that they would be laid off

• The company has signed a contract with Indian outsourcing firm Wipro that will take over the employees’ jobs. According to reports, the
workers, before their exit from the company on April 22, are required to train their lower-wage foreign replacements to do their jobs

• Abbott uses the H-1B visa program to outsource jobs to foreign workers

IT Layoffs Criticism
• In March 2016, according to Sen. Dick Durbin's letter, 180 Abbott employees were given 60 days' notice and told their last day will be April.
However, Abbott put the number of impacted IT employees at fewer than 150

“It should go without saying that such harsh and insensitive conduct is not justified by whatever marginal financial benefit might accrue to your
company, which is already making billions of dollars in profits every year, Once again, I urge you to restore the jobs of these 180 American IT
employees who have served your company with skill and loyalty for many years.”

– Sen. Dick Durbin (D-IL), Senator of Illinois, 2016 in a letter to CEO Miles D. White

| 27
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Technology Landscape (1/10)
• SAP

‒ Abbott Laboratories Ireland engaged SAPRO to provide SAP Finance expertise as part of their SAP implementation

‒ Abbott Manufacturing Operations (Sligo) engage SAPRO to provide Finance Project Management expertise as part of
SAP implementation

‒ Abbott uses SAP Afaria to maintain security and provide centralized control and management of its Microsoft
Windows-based tablets

‒ Abbott appears to be using SAP Fieldglass to optimize their unique services procurement and external workforce
management programs

• IBM:

‒ Abott uses IBM Domino, a server application platform used for enterprise e-mail, messaging, scheduling and
collaboration

‒ Abbott has appeared to be using IBM Rational software. The software helps organizations succeed by supporting
DevOps, continuous engineering, and enterprise modernization best practices

Source: Company website and reports, industry reporting | 28

Abbott Laboratories
Technology Landscape (2/10)
‒ Abbott appears to have deployed IBM Websphere. IBM Websphere is a large IBM product family that provides Web-
based access to an organization's application software

• Microsoft:

‒ Abbott appears to be using Microsoft IIS (Internet Information Services). IIS is an extensible web server created by
Microsoft for use with Windows NT family

• Oracle:

‒ Abbott Diagnostics selected Oracles Siebel CRM Technology because of its comprehensive suite of e-business
functionality. Siebel Medical’s industry specific functionality will decrease their implementation costs and accelerate
their time to return on investment

‒ Abbott choose Oracle Taleo Cloud Service to recruit top performers with the right cloud talent skills

Source: Company website and reports, industry reporting | 29

Abbott Laboratories
Technology Landscape (3/10)
• Abbott Laboratories implemented AWARDS-BA, the solution from Brentech Data Systems, providing direct access to
doctors, pharmacies and hospitals to a range of its specialist products. The AWARDS-BA SaaS Electronic Ordering
Solution provided facility for over 1,500 customers to benefit from DTP (Direct To Pharmacy) on line ordering
immediately

• Abbott deployed HPE Applications Lifecycle Management and HPE Quality Center Software

‒ HPE Software products implemented are as follows:

o HPE Applications Lifecycle Management: Abbott has begun using HPE ALM to manage hardware verification, in
addition to the software verification using the solution’s native testing tools. This gives Abbott a more
comprehensive, end-to-end view into its diagnostic instrument QA processes

o HPE Quality Center: Abbott benefitted from the HPE Quality Center as it Manages Quality Assurance (QA)
processes for its diagnostic instrument manufacturing organization including creating, running and managing
instrument software test cases; and tracking defects and test results

| 30
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Technology Landscape (4/10)
o HPE eSignature: The HPE eSignature solution allowed Abbott to meet FDA requirements related to
demonstrating that its testing records are authenticated and protected. And because it is an integrated, HPE-
developed solution, HPE eSignature relieves Abbott of the overhead and unpredictability associated with
managing a third-party plug-in

‒ In the future, Abbott also plans to use HPE ALM to manage testing and results reporting of its in-house
applications

• Abbott choose CSC for their custom software development

‒ Abbott also appears to be using CSC Intact Software

• Abbott appears to be using Citrix software

• Abbott appears to be using iRise. Using iRise the Abbott teams collaborate better,identify and resolve issues early,
virtually eliminate rework, and reducing overall application development costs

• Abbott Laboratories appears to be a customer of Accenture which is serving as program manager for the group

• Abbott appears to be a client of Cognizant. Cognizant was among 24 companies recognized by Abbott for “supplier
excellence” during calendar year 2007

| 31
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Technology Landscape (5/10)
• Abbott appears to be a client of AlfaTech

• Abbott used services from Salesforce to create Abbott Vascular GFIM App to communicate with the customers in a
new way

• Abbott appears to have used Magneto for B2B e-commerce in the US via Magneto online

• Abbott Laboratories of Venezuela in conjunction with IMVINET, implemented a network of digital billboards in
ABBOTT Caracas headquarters, with the aim of timely informing employees through the Digital Signage screens

• Abbott is a customer of Schneider Electric. Schneider Electric is a manufacturer of facility automation systems for the
Biotech and Pharmaceutical markets and their flagship product, the Andover ContinuumTM Facility Management
System, provides HVAC control, security alarm monitoring, access control, badging, video surveillance, and
environmental monitoring for regulated facilities worldwide

• Abbott deployed Acumatica. Accumatica provided cloud business solutions to Abbott Nutrition

• Abbott appears to be a using BCD Software

| 32
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Technology Landscape (6/10)
• Abbott Labs selected looksoftware’s snap for Business Planning and Control System (BPCS)

“We selected looksoftware to modernize our BPCS investments because we can easily snap our customized BPCS
code into multiple front-ends using looksoftware’s multi-channel support for rich, thin and mobile clients.”

- Jeffrey Tan , Data Center System Administrator

• Abbott appears to be a customer of Simitri

• Abbott appears to be using Linomas’s RPG Toolbox

• Abbott implemented GS1 Standards to efficiently manage and share accurate product data with regulators and
trading partners

‒ This model enabled Abbott to utilize Global Location Numbers (GLNs) for company locations and Global Trade Item
Numbers (GTINs) for its products. The company has also registered these GTINs and their product attributes in the
Global Data Synchronization Network (GDSN) for accurate data sharing with trading partners

| 33
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Technology Landscape (7/10)
‒ The benefits as achieved by Abbott are as below:

o Abbott’s customers, such as group purchasing organizations, have responded positively to the company’s GDSN
implementation since it will help them streamline their ordering processes and help minimize errors and
rework

o Using GTINs and the GDSN, one of Abbott’s trading partners, a major healthcare provider, affirmed an improved
order-to-cash process that is more accurate and efficient

o Abbott is well positioned to support compliance with the FDA Unique Device Identification (UDI) regulation
with its implementation of GTINs and the GDSN

o By using GS1 Standards, Abbott helps providers ensure patients receive the right products, strengthening
patient safety practices

• Abbott deployed Qstream Health Care Solutions. Qstream combines mobile, science and gamification in
a powerfully simple solution that’s helps healthcare leaders reinforce the knowledge and skills that matter most

• Abbott appears to be using Cloudingo, a cloud-based SaaS that connects to salesforce.com and allows system
administrators to scan their entire database for similar or duplicate records

| 34
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Technology Landscape (8/10)
• Abbott is using WANdisco Fusion, a data replication product for Hadoop

• Abbott implemented Apache Cordova command-line which runs on Node.js and is available on NPM

• Abbott appears to be using Stormpath for their user management service

• Abbott appears to be using Inkling intelligence solutions to make operational and strategic decisions

• Abbott appears to be a client of Studio One that develops custom content marketing programs targeted to
advertiser's audiences

• Abbott is a customer of Box that enables the company to share files online, provides unlimited storage, customer
branding and administrative controls

• Abbott Laboratories used Car Fleet Control's Eurofleet fleet management software system for its 400-car fleet.
Specialist software was essential to overcome the paper-intensive management of the company's outright-purchased
fleet

• Abbott appears to be a using AssurX Solutions. AssurX is a software platform that helps professionals run their
business by delivering solutions developed with an understanding of the clients’ needs

| 35
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Technology Landscape (9/10)
DATA ANALYTICS/ DATABASES
• Big Data/NoSQL: Apache Hbase, Apache Pig, Cloudera, Hadoop, Hadoop HDFS, Hadoop MapReduce, Hive, HP Vertica Analytic Database, MapR, MongoDB

• Business Intelligence: Actuate, BitSight Technologies, Cognos Enterprise, Cognos Series 7, DataWatch Monarch, Dundas Data Visualization, IBM Cognos,
IBM Cognos BI, IBM Cognos EP, IBM Cognos Impromptu

• Data Modeling/Mining: CA Erwin, Hyperion Essbase, IBM SPSS Statistics, Informatica PowerCenter, Informatica PowerExchange, Microsoft SSIS, OLAP
Server, Omniture Data Warehouse, Oracle Data Warehousing, Oracle Designer

DATA INFRASTRUCTURE
• Cloud Systems: Accela Software, CA AutoSys, CiRBA, Citrix NetScaler, Google Cloud Apps, node.js, OpenStack, Opscode Chef, Oracle Enterprise Manager,
PlateSpin

• Desktop Virtualization: Citrix Receiver, Citrix XenApp, Citrix XenDesktop, DameWare, VMware Thinstall, VMware Thinstall/ThinApp, VMware VDI, VMware
Workstation, Workstation, WSUS

• Email Hosting: GoDaddy (mail server), GoDaddy Email, Google (mail server), Mandrill, Microsoft (mail server), SMTP Server (inhouse)

| 36
Source: Industry Reporting; Group Website and Report
Abbott Laboratories
Technology Landscape (10/10)
DATA STORAGE
• Data Backup: Acronis Software, CA ARCserve, CommVault, EMC Avamar, EMC Networker, Oracle 10g R2, Oracle RMAN, Symantec Backup Exec, Symantec
Enterprise Vault, Symantec NetBackup

• Disaster Recovery: Recovery Point, Symantec Veritas Cluster Server, Veeam

• Enterprise Storage: EMC Data Domain, HDS Storage, Hitachi, Hitachi Storage, HP StorageWorks, HP StorageWorks Enterprise Virtual Array, HP
StorageWorks EVA, HP Tape Libraries, IBM Spectrum Protect, IBM Tivoli Storage Manager

ENTERPRISE/ ERP
• CRM: AMO, Ardexus, Avaya Aura, Avaya Aura Call Center Elite, Avaya Call Management System, Avaya Contact Center Control Manager, Bazaarvoice, CMS,
KANA, Microsoft CRM
• Enterprise Resource Planning (ERP): Agilysys, Enterprise Resource Planning, Epicor Avante, Infor ERP Baan, Infor Lawson, Infor LX, Microsoft Dynamics,
mySAP ERP, Oracle 10g Enterprise Edition, Oracle EBS
• Enterprise Systems Support: CA Project Portfolio Management (PPM), IBM Rational DOORS, iManage, Kanban, Microsoft Enterprise Project Management,
Oracle Instantis, Primavera Enterprise Project Portfolio Management, ProChain, Quest, SAP Applications

INDUSTRY SOFTWARE
• Clinical: gMED, MicroMD, TransPerfect Trial Interactive

| 37
Source: Industry Reporting; Group Website and Report
Industry Insight| Account Insight | Competition Intelligence
www.businessbrainz.com